Syk

21 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Syk Inhibitor

    R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.
  2. Syk Inhibitor

    R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.
  3. Syk Inhibitor

    R935788 (Fostamatinib disodium) is a potent orally available inhibitor of Syk that inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
  4. Syk Inhibitor

    BAY 61-3606 is a cell-permeable imidazopyrimidine compound that acts as a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
  5. Syk inhibitor

    R788 (Fostamatinib) is an important spleen tyrosine kinase (Syk) inhibitor, showing efficacy against kinase-mediated IgG Fc gamma receptor signaling.
  6. Syk inhibitor

    P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.
  7. Syk Inhibitor

    Piceatannol is an anti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-??B activation and gene expression.
  8. Syk Inhibitor

    PRT2607, also known as PRT062607, P505-15, and BIIB057, is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.
  9. SYK inhibitor

    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
  10. Syk inhibitor

    GS-9973 is an oral inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity.
  11. Dual Syk and JAK inhibitor

    PRT062070 is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types.
  12. Syk inhibitor

    R112 is a Syk inhibitor. R112 inhibited degranulation induced by anti-IgE cross-linking in mast cells and also blocked leukotriene C4 production and all proinflammatory cytokines tested.
  13. Syk Inhibitor

    BAY 61-3606 is a potent (Ki = 7.5 nM) and selective inhibitor of Syk kinase.
  14. Syk inhibitor

    PRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.
  15. Src/Syk inhibitor

    MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
  16. ATP-competitive SYK inhibitor

    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
  17. SYK/JAK inhibitor

    Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM.
  18. SYK/FLT3 inhibitor

    TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.
  19. Syk inhibitor

    Fostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  20. Syk inhibitor

    TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.
  21. Syk/PI3K inhibitor

    SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.

21 Items

per page
Set Descending Direction